Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Effect of TGF-β Combined With INS-PI3K-AKT Signaling Pathway Related Proteins (ADNP, MAP6, Pgc-1α) for POD in Diabetes Patients

NCT06426953 is registered in ClinicalTrials.gov with Xie Kangjie as lead sponsor.

NCT NCT06426953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06426953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Effect of TGF-β Combined With INS-PI3K-AKT Signaling Pathway Related Proteins (ADNP, MAP6, Pgc-1α) for POD in Diabetes Patients
Lead sponsor
Xie Kangjie
Phase
Observational
Overall status
Recruiting
Start date
May 20, 2024
Completion date
August 30, 2026
Enrollment
180 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, postoperative delirium